AU2020313965B2 - Polymorphs of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide - Google Patents

Polymorphs of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide

Info

Publication number
AU2020313965B2
AU2020313965B2 AU2020313965A AU2020313965A AU2020313965B2 AU 2020313965 B2 AU2020313965 B2 AU 2020313965B2 AU 2020313965 A AU2020313965 A AU 2020313965A AU 2020313965 A AU2020313965 A AU 2020313965A AU 2020313965 B2 AU2020313965 B2 AU 2020313965B2
Authority
AU
Australia
Prior art keywords
polymorph
polymorphic form
inden
dihydro
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020313965A
Other languages
English (en)
Other versions
AU2020313965A1 (en
Inventor
Denise Andersen
Qi Gao
Matthew PFEIFFER
Norma TOM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71995103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2020313965(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of AU2020313965A1 publication Critical patent/AU2020313965A1/en
Application granted granted Critical
Publication of AU2020313965B2 publication Critical patent/AU2020313965B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020313965A 2019-07-17 2020-07-16 Polymorphs of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide Active AU2020313965B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875350P 2019-07-17 2019-07-17
US62/875,350 2019-07-17
PCT/US2020/042387 WO2021011807A1 (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide

Publications (2)

Publication Number Publication Date
AU2020313965A1 AU2020313965A1 (en) 2022-03-03
AU2020313965B2 true AU2020313965B2 (en) 2026-06-18

Family

ID=71995103

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020313965A Active AU2020313965B2 (en) 2019-07-17 2020-07-16 Polymorphs of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide

Country Status (25)

Country Link
US (1) US20220315571A1 (cg-RX-API-DMAC10.html)
EP (2) EP4487911A1 (cg-RX-API-DMAC10.html)
JP (2) JP7624431B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220084008A (cg-RX-API-DMAC10.html)
CN (3) CN118908951A (cg-RX-API-DMAC10.html)
AU (1) AU2020313965B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022000494A2 (cg-RX-API-DMAC10.html)
CA (1) CA3144975A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022000054A1 (cg-RX-API-DMAC10.html)
DK (1) DK3999180T3 (cg-RX-API-DMAC10.html)
ES (1) ES2980885T3 (cg-RX-API-DMAC10.html)
FI (1) FI3999180T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240713T1 (cg-RX-API-DMAC10.html)
HU (1) HUE066891T2 (cg-RX-API-DMAC10.html)
IL (1) IL289875B1 (cg-RX-API-DMAC10.html)
LT (1) LT3999180T (cg-RX-API-DMAC10.html)
MX (1) MX2022000504A (cg-RX-API-DMAC10.html)
PH (1) PH12022550123A1 (cg-RX-API-DMAC10.html)
PL (1) PL3999180T3 (cg-RX-API-DMAC10.html)
PT (1) PT3999180T (cg-RX-API-DMAC10.html)
RS (1) RS65611B1 (cg-RX-API-DMAC10.html)
SI (1) SI3999180T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400224T1 (cg-RX-API-DMAC10.html)
TW (1) TWI865562B (cg-RX-API-DMAC10.html)
WO (1) WO2021011807A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
JP2024530111A (ja) 2021-08-03 2024-08-16 サイトキネティックス, インコーポレイテッド アフィカムテンを調製するための工程
US20240091203A1 (en) 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
JP2025525913A (ja) 2022-08-04 2025-08-07 サイトキネティックス, インコーポレイテッド 閉塞性肥大型心筋症を治療するための方法
WO2024134498A1 (en) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Solid state forms of aficamten and process for preparation thereof
CN120712262A (zh) * 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
WO2025198687A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) * 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024530111A (ja) * 2021-08-03 2024-08-16 サイトキネティックス, インコーポレイテッド アフィカムテンを調製するための工程

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) * 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Also Published As

Publication number Publication date
IL289875B1 (en) 2026-05-01
CA3144975A1 (en) 2021-01-21
NZ784930A (en) 2025-03-28
IL289875A (en) 2022-03-01
EP4487911A1 (en) 2025-01-08
EP3999180B1 (en) 2024-05-08
JP2022540668A (ja) 2022-09-16
KR20220084008A (ko) 2022-06-21
TWI865562B (zh) 2024-12-11
CN114555590A (zh) 2022-05-27
CN118908951A (zh) 2024-11-08
ES2980885T3 (es) 2024-10-03
JP2025061484A (ja) 2025-04-10
HRP20240713T1 (hr) 2024-09-13
EP3999180A1 (en) 2022-05-25
MX2022000504A (es) 2022-02-10
US20220315571A1 (en) 2022-10-06
CN114555590B (zh) 2024-09-10
BR112022000494A2 (pt) 2022-03-03
PH12022550123A1 (en) 2022-12-19
JP7755090B2 (ja) 2025-10-15
PT3999180T (pt) 2024-06-25
AU2020313965A1 (en) 2022-03-03
CL2022000054A1 (es) 2022-10-07
LT3999180T (lt) 2024-08-26
JP7624431B2 (ja) 2025-01-30
PL3999180T3 (pl) 2024-09-23
WO2021011807A1 (en) 2021-01-21
DK3999180T3 (da) 2024-05-21
RS65611B1 (sr) 2024-07-31
FI3999180T3 (fi) 2024-06-18
SMT202400224T1 (it) 2024-07-09
TW202116763A (zh) 2021-05-01
SI3999180T1 (sl) 2024-07-31
HUE066891T2 (hu) 2024-09-28
CN119119018A (zh) 2024-12-13